Cellectis SA (XPAR:ALCLS)
€ 1.48 -0.02 (-1.33%) Market Cap: 148.14 Mil Enterprise Value: -14.65 Mil PE Ratio: 0 PB Ratio: 1.29 GF Score: 44/100

Cellectis SA at Goldman Sachs Healthcare Conference Transcript

Jun 15, 2023 / 05:00PM GMT
Release Date Price: €1.91 (-0.16%)
Anoumid Vaziri
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good morning, everyone. I'm Anoumid Vaziri. And I'm joined on stage with Bing Wang, CFO of Cellectis. Bing, thank you for being here with us today.

Bing C. Wang
Cellectis S.A. - CFO

Thank you for inviting me.

Questions & Answers

Anoumid Vaziri
Goldman Sachs Group, Inc., Research Division - Research Analyst

And so to start, Cellectis is a clinical stage biotech company using its TALENs gene editing platform to develop allogeneic cell therapies. Could you provide an overview of your portfolio, both on the partnered and the wholly-owned assets and then discuss how you're differentiated as a company in the cell therapy space?

Bing C. Wang
Cellectis S.A. - CFO

Great. Thank you very much. So I would say we would put our portfolio in 3 buckets. The first is our wholly-owned clinical asset. So we have UCART22 going after ALL. We have UCART123 going after AML. We can go into that in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot